

# Draft Agenda – Jerez 2012- Open Session of the EuFMD Standing Technical Committee

**eofmd**

europa  
european commission for the  
control of foot-and-mouth disease



**EuFMD 2012**  
OPEN SESSION

**Appliance of science in  
the Progressive Control  
of FMD**



**Where the world  
comes to talk  
FMD science**

**JEREZ DE LA FRONTERA  
SPAIN  
29-31 OCTOBER 2012**

EuFMD

Jerez de la Frontera

8/1/2012

**::Open Session of the EuFMD Standing Technical Committee::**

**Focus on issues affecting FMD control in FMD free regions**

<b>1</b>	<p>Waiting periods for reinstatement of FMD-free status after vaccination-to-live:</p> <ul style="list-style-type: none"> <li>❖ Two technical papers examining the basis for waiting periods after use of vaccination-to-live in free countries and achievement of desired outcomes of confidence in disease freedom.</li> </ul>
<b>2</b>	<p>European Wild boar and their role in disease transmission : Lessons learnt and policy implications:</p> <ul style="list-style-type: none"> <li>❖ Two papers considering the lessons learnt from the FMD surveillance in wild boar in Bulgaria and Turkey in 2011-12 and the issues of improving surveillance for FMD and other infections in wild boar.</li> </ul>
<b>3</b>	<p>Economic evaluation of FMD emergency management options and control measures in Europe: implications for science and policy:</p> <ul style="list-style-type: none"> <li>❖ Two papers considering the implications of recent epidemiologic-economic modeling of FMD emergency management options in European countries.</li> </ul>

**::Open Session of the EuFMD Special Committee on Research::**

**(formerly the “Research Group”)\***

<b>1</b>	<p><b>Progressive Control Pathway for FMD (PCP)</b>, technical developments and issues</p> <ul style="list-style-type: none"> <li>❖ Three invited papers reviewing how the PCP has been applied in endemic countries by EuFMD , the methodological issues and developments in identifying FMD risks and disease impact, risk management options, monitoring and evaluation of progress. Includes progress on developing a socio-economics toolbox to identify issues and potential solutions with private and public stakeholders in FMD control.</li> </ul>
<b>2</b>	<p><b>FMD epidemiology</b>; transmission, virus circulation, risk factors (17)</p> <ul style="list-style-type: none"> <li>❖ Keynote on viral threat emergence, and submitted papers on FMD epidemiology , including surveillance for new threats, experimental, molecular epidemiology, field studies.</li> </ul>
<b>3</b>	<p><b>FMD monitoring and surveillance</b> – experience, methods and approaches (6)</p> <ul style="list-style-type: none"> <li>❖ Submitted papers on FMD monitoring (focus on monitoring changes threatening health status) and surveillance (focus on detection of new events requiring response, in free countries or entry of exotic serotypes). Latter section includes issues of             <ol style="list-style-type: none"> <li>a. Efficiency in FMD case detection, by veterinary surveillance visits and sampling, in domestic animals and wildlife;</li> <li>b. Engaging livestock sector and animal health workers in surveillance during an animal health crisis: new tools for effective communication;</li> <li>c. the potential use of bulk milk screening (pooled sampling for pre-clinical diagnosis...).</li> </ol> </li> </ul>
<b>4</b>	<p><b>FMD vaccines</b> (6)</p> <ul style="list-style-type: none"> <li>❖ Submitted papers on FMD vaccines: including selection, production, stability, cross-protection, quality control, duration of immunity, alternatives to challenge.</li> </ul>
<b>5</b>	<p><b>Effectiveness of vaccination programmes</b> (5)</p> <ul style="list-style-type: none"> <li>❖ Keynote and submitted papers on the monitoring of vaccination programmes, including measurement of FMD vaccine effectiveness against clinical disease.</li> </ul>
<b>6</b>	<p><b>Diagnostic developments</b> and laboratory networks (10)</p> <ul style="list-style-type: none"> <li>❖ Keynote papers on development of new diagnostic assays and on the application of the EuFMD Minimum Standards for FMD laboratory biorisk management. Open papers on development, validation and evaluation of diagnostics, and from leaders in the FMD lab networks in the seven virus pools.</li> </ul>
<b>7</b>	<p><b>FMD management</b> and the evaluating the impact of control measures (6)</p> <ul style="list-style-type: none"> <li>❖ Submitted papers from free and endemic countries; includes the issue of development of models for FMD spread and management options for use in endemic countries.</li> </ul>
<b>8</b>	<p><b>Complementary research</b>: pathogenesis, next generation methods, insights and ideas from research (6)</p> <ul style="list-style-type: none"> <li>❖ Submitted papers from basic or cutting edge research that improve understanding of FMD biology, risk and have potential to of high relevance to understanding FMD and indicate trends and ideas from technical fields of relevance to future management.</li> </ul>

*The approximate number of open (submitted) papers is given in brackets. Overall around 60 submitted papers will be accepted for oral presentation; the time allocated to each item will depend on the number and importance of the offered papers.*